Ju Jie, Wismans Leonoor V, Mustafa Dana A M, Reinders Marcel J T, van Eijck Casper H J, Stubbs Andrew P, Li Yunlei
Department of Pathology & Clinical Bioinformatics, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands.
Department of Surgery, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands.
iScience. 2021 Nov 10;24(12):103415. doi: 10.1016/j.isci.2021.103415. eCollection 2021 Dec 17.
A major challenge for treating patients with pancreatic ductal adenocarcinoma (PDAC) is the unpredictability of their prognoses due to high heterogeneity. We present Multi-Omics DEep Learning for Prognosis-correlated subtyping (MODEL-P) to identify PDAC subtypes and to predict prognoses of new patients. MODEL-P was trained on autoencoder integrated multi-omics of 146 patients with PDAC together with their survival outcome. Using MODEL-P, we identified two PDAC subtypes with distinct survival outcomes (median survival 10.1 and 22.7 months, respectively, log rank p = 1 × 10), which correspond to DNA damage repair and immune response. We rigorously validated MODEL-P by stratifying patients in five independent datasets into these two survival groups and achieved significant survival difference, which is superior to current practice and other subtyping schemas. We believe the subtype-specific signatures would facilitate PDAC pathogenesis discovery, and MODEL-P can provide clinicians the prognoses information in the treatment decision-making to better gauge the benefits versus the risks.
治疗胰腺导管腺癌(PDAC)患者面临的一个主要挑战是,由于高度异质性,其预后具有不可预测性。我们提出了用于预后相关亚型分析的多组学深度学习(MODEL-P)方法,以识别PDAC亚型并预测新患者的预后。MODEL-P在自动编码器集成的146例PDAC患者的多组学数据及其生存结果上进行训练。使用MODEL-P,我们识别出了两种具有不同生存结果的PDAC亚型(中位生存期分别为10.1个月和22.7个月,对数秩检验p = 1×10),分别对应DNA损伤修复和免疫反应。我们通过将五个独立数据集中的患者分层到这两个生存组中,对MODEL-P进行了严格验证,并实现了显著的生存差异,这优于当前的实践方法和其他亚型分析模式。我们相信,亚型特异性特征将有助于发现PDAC的发病机制,并且MODEL-P可以在治疗决策中为临床医生提供预后信息,以便更好地权衡收益与风险。